Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon β

被引：241

作者：

Bielekova, B

Richert, N

Howard, T

Blevins, G

Markovic-Plese, S

McCartin, J

Würfel, J

Ohayon, J

Waidmann, TA

McFarland, HF

Martin, R

机构：

[1] NINDS, Neuroimmunol Branch, NIH, Bethesda, MD 20892 USA

[2] Univ N Carolina, Dept Neurol, Chapel Hill, NC 27599 USA

[3] Humboldt Univ, Inst Neuroimmunol, Charite, D-10117 Berlin, Germany

[4] NCI, Metab Branch, NIH, Bethesda, MD 20892 USA

来源：

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA | 2004年 / 101卷 / 23期

关键词：

D O I：

10.1073/pnas.0402653101

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Identifying effective treatment combinations for MS patients failing standard therapy is an important goal. We report the results of a phase II open label baseline-to-treatment trial of a humanized monoclonal antibody against CD25 (daclizumab) in 10 multiple sclerosis patients with incomplete response to IFN-beta therapy and high brain inflammatory and clinical disease activity. Daclizumab was very well tolerated and led to a 78% reduction in new contrast-enhancing lesions and to a significant improvement in several clinical outcome measures.

引用

页码：8705 / 8708

页数：4

共 16 条

[1] Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: Results of a phase II clinical trial with an altered peptide ligand [J].

Bielekova, B ;

Goodwin, B ;

Richert, N ;

Cortese, I ;

Kondo, T ;

Afshar, G ;

Gran, B ;

Eaton, J ;

Antel, J ;

Frank, JA ;

McFarland, HF ;

Martin, R .

NATURE MEDICINE, 2000, 6 (10) :1167-1175

[2] Prospective study on the relationship between infections and multiple sclerosis exacerbations [J].

Buljevac, D ;

Flack, HZ ;

Hop, WCJ ;

Hijdra, D ;

Laman, JD ;

Savelkoul, HFJ ;

van der Meché, FGA ;

van Doorn, PA ;

Hintzen, RQ .

BRAIN, 2002, 125 :952-960

[3] METHOD FOR QUANTIFICATION OF BRAIN, VENTRICULAR, AND SUBARACHNOID CSF VOLUMES FROM MR IMAGES [J].

DECARLI, C ;

MAISOG, J ;

MURPHY, DGM ;

TEICHBERG, D ;

RAPOPORT, SI ;

HORWITZ, B .

JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY, 1992, 16 (02) :274-284

[4] A pilot study of recombinant insulin-like growth factor-1 in seven multiple sclerosis patients [J].

Frank, JA ;

Richert, N ;

Lewis, B ;

Bash, C ;

Howard, T ;

Civil, R ;

Stone, R ;

Eaton, J ;

McFarland, H ;

Leist, T .

MULTIPLE SCLEROSIS, 2002, 8 (01) :24-29

[5]

KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444

[6] A controlled trial of natalizumab for relapsing multiple sclerosis. [J].

Miller, DH ;

Khan, OA ;

Sheremata, WA ;

Blumhardt, LD ;

Rice, GPA ;

Libonati, MA ;

Willmer-Hulme, AJ ;

Dalton, CM ;

Miszkiel, KA ;

O'Connor, PW .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (01) :15-23

[7] Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration [J].

Nussenblatt, RB ;

Thompson, DJS ;

Li, ZQ ;

Peterson, JS ;

Robinson, RR ;

Shames, RS ;

Nagarajan, S ;

Tang, MT ;

Mailman, M ;

Velez, G ;

Roy, C ;

Levy-Clarke, GA ;

Suhler, EB ;

Djalilian, A ;

Sen, HN ;

Al-Khatib, S ;

Ursea, R ;

Srivastava, S ;

Bamji, A ;

Mellow, S ;

Sran, P ;

Waldmann, TA ;

Buggage, RR .

JOURNAL OF AUTOIMMUNITY, 2003, 21 (03) :283-293

[8] Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: A phase I/II clinical trial [J].

Nussenblatt, RB ;

Fortin, E ;

Schiffman, R ;

Rizzo, L ;

Smith, J ;

Van Veldhisen, P ;

Sran, P ;

Yaffe, A ;

Goldman, CK ;

Waldmann, TA ;

Whitcup, SM .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (13) :7462-7466

[9] Correspondence of closest gradient voxels - A robust registration algorithm [J].

Ostuni, JL ;

Levin, RL ;

Frank, JA ;

DeCarli, C .

JMRI-JOURNAL OF MAGNETIC RESONANCE IMAGING, 1997, 7 (02) :410-415

[10] INTERFERON BETA-1B IS EFFECTIVE IN RELAPSING-REMITTING MULTIPLE-SCLEROSIS .2. MRI ANALYSIS RESULTS OF A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL [J].

PATY, DW ;

LI, DKB ;

DUQUETTE, P ;

GIRARD, M ;

DESPAULT, L ;

DUBOIS, R ;

KNOBLER, RL ;

LUBLIN, FD ;

KELLEY, L ;

FRANCIS, GS ;

LAPIERRE, Y ;

ANTEL, J ;

FREEDMAN, M ;

HUM, S ;

GREENSTEIN, JI ;

MISHRA, B ;

MULDOON, J ;

WHITAKER, JN ;

EVANS, BK ;

LAYTON, B ;

SIBLEY, WA ;

LAGUNA, J ;

KRIKAWA, J ;

PATY, DW ;

OGER, JJ ;

KASTRUKOFF, LF ;

MOORE, GRW ;

HASHIMOTO, SA ;

MORRISON, W ;

NELSON, J ;

GOODIN, DS ;

MASSA, SM ;

GUTTERIDGE, E ;

ARNASON, BGW ;

NORONHA, A ;

REDER, AT ;

MARTIA, R ;

EBERS, GC ;

RICE, GPA ;

LESAUX, J ;

JOHNSON, KP ;

PANITCH, HS ;

BEVER, CT ;

CONWAY, K ;

WALLENBERG, JC ;

BEDELL, L ;

VANDENNOORT, S ;

WEINSHENKER, B ;

WEISS, W ;

REINGOLD, S .

NEUROLOGY, 1993, 43 (04) :662-667

← 1 2 →